Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.9
Journals
JCM
Special Issues
Clinical Research Advances in Thoracic Surgery
share announcement

Clinical Research Advances in Thoracic Surgery

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".

Deadline for manuscript submissions: 23 October 2024 | Viewed by 719

Special Issue Editor

Dr. Hideki Ujiie

E-Mail Website
Guest Editor
Department of Thoracic Surgery, Hokkaido University, Hokkaido, Japan
Interests: neoadjuvant therapies; immunotherapies; targeted therapies; biomarkers; personalized medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I would like to introduce the Special Issue of “Clinical Research Advances in Thoracic Surgery”.

There are several ongoing and recently completed clinical research advances in the field of thoracic surgery. These advancements aimed to improve surgical techniques, patient outcomes and the quality of life for thoracic surgery patients.

This Special Issue will focus on the following three topics:

  1. Neoadjuvant therapies: Clinical trials are investigating the use of neoadjuvant therapies, such as chemotherapy and radiation, before surgery for lung cancer and other thoracic malignancies. Neoadjuvant treatment aims to shrink tumors, increase the chance of complete surgical resection and potentially improve long-term outcomes for patients.
  2. Immunotherapies and targeted therapies: Research is ongoing to explore the role of immunotherapies and targeted therapies in combination with surgical interventions for thoracic cancers. These treatments can help enhance the body's immune response against cancer cells and specifically target genetic mutations in cancer cells, potentially improving treatment outcomes.
  3. Biomarkers and personalized medicine: Clinical research is exploring the use of biomarkers and genomic profiling to guide treatment decisions and tailor therapies for individual patients. Identifying specific biomarkers can help predict treatment responses and improve the selection of appropriate therapies.

It is important to note that the field of medicine, including thoracic surgery, is continuously evolving. New advancements may have emerged since my last update, and I would appreciate your contributions to these topics.

Dr. Hideki Ujiie
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neoadjuvant therapies
  • immunotherapies
  • targeted therapies
  • biomarkers
  • personalized medicine

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

10 pages, 516 KiB  
Protocol
Dose Optimization of Intravenous Indocyanine Green for Malignant Lung Tumor Localization
by Hideki Ujiie, Ryohei Chiba, Akihiro Sasaki, Shunsuke Nomura, Haruhiko Shiiya, Shohei Otsuka, Hiroshi Yamasaki, Aki Fujiwara-Kuroda, Kazuto Ohtaka, Masato Aragaki, Kazufumi Okada, Yuma Ebihara and Tatsuya Kato
J. Clin. Med. 2024, 13(10), 2807; https://doi.org/10.3390/jcm13102807 - 10 May 2024
Viewed by 486
Abstract
Background: Intravenously administered indocyanine green (ICG) accumulates in lung tumors, facilitating their detection via a fluorescence spectrum measurement. This method aids in identifying tumor locations that are invisible to the naked eye. We aim to determine the optimal ICG dose and administration method [...] Read more.
Background: Intravenously administered indocyanine green (ICG) accumulates in lung tumors, facilitating their detection via a fluorescence spectrum measurement. This method aids in identifying tumor locations that are invisible to the naked eye. We aim to determine the optimal ICG dose and administration method for accurate tumor identification during lung resection surgeries, utilizing a novel ICG fluorescence spectroscopy system for precise tumor localization. Materials and Methods: ICG should be dissolved in the provided solution or distilled water and administered intravenously approximately 24 h before surgery, beginning with an initial dose of 0.5 mg/kg. If the tumor detection rate is insufficient, the dose may be gradually increased to a maximum of 5.0 mg/kg to determine the optimal dosage for effective tumor detection. This fluorescence spectroscopy during surgery may reveal additional lesions that remain undetected in preoperative assessments. The primary endpoint includes the correct diagnostic rate of tumor localization. The secondary endpoints include the measurement of the intraoperative ICG fluorescence spectral intensity in lung tumors, the assessment of the operability and safety of intraperitoneal ICG administrations, the measurement of the ICG fluorescence spectral intensity in surgical specimens, the comparison of the spectral intensity in lung tissues during collapse and expansion, the correlation between ICG camera images and fluorescence spectral intensity, and the comparison of fluorescence analysis results with histopathological findings. The trial has been registered in the jRCT Clinical Trials Registry under the code jRCTs011230037. Results and Conclusions: This trial aims to establish an effective methodology for localizing and diagnosing malignant lung tumors, thereby potentially improving surgical outcomes and refining treatment protocols. Full article
(This article belongs to the Special Issue Clinical Research Advances in Thoracic Surgery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop